anti-cd19 monoclonal antibodies: a new approach to lymphoma therapy

نویسندگان

fatemeh naddafi pharmaceutical sciences research center, shahid beheshti university of medical sciences, tehran, iran.سازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (shahid beheshti university of medical sciences)

fatemeh davami biotechnology research center, pasteur institute of iran, tehran, iran.سازمان اصلی تایید شده: انستیتو پاستور ایران (pasteur institute of iran)

چکیده

cd19 is expressed on b- lineage cells and follicular dendritic cells and plays a key role in b cell malignancies and autoimmune diseases. thus, it has been considered as potential target for several monoclonal antibodies (mabs). for decades, chemotherapy has been known as one of the major antitumor therapies eradicating high proliferative tumor cells. but, anti- cd19 mabs developed for treating cd19- positive lymphomas and autoimmune diseases would rank among the most novel area of research and development in the pharmaceutical industry. moreover, several anti- cd19 mabs are currently being tested in various clinical trials and this review provides an overview of the research accomplished so far.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy

CD19 is expressed on B- lineage cells and follicular dendritic cells and plays a key role in B cell malignancies and autoimmune diseases. Thus, it has been considered as potential target for several monoclonal antibodies (mAbs). For decades, chemotherapy has been known as one of the major antitumor therapies eradicating high proliferative tumor cells. But, anti- CD19 mAbs developed for treating...

متن کامل

Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy

CD19 is expressed on B- lineage cells and follicular dendritic cells and plays a key role in B cell malignancies and autoimmune diseases. Thus, it has been considered as potential target for several monoclonal antibodies (mAbs). For decades, chemotherapy has been known as one of the major antitumor therapies eradicating high proliferative tumor cells. But, anti- CD19 mAbs developed for treating...

متن کامل

Novel CD20 monoclonal antibodies for lymphoma therapy

Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-cell lymphoma. However, suboptimal response and /or resistance to rituximab have remained a challenge in the therapy of B-cell non-Hodgkin's lymphom...

متن کامل

Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.

To study the immunotherapeutic potential of monoclonal antibodies (mAbs) directed against the human pan-B-cell antigen CD19, a xenotransplantation model was developed in which the human Burkitt's cell line Daudi is s.c. transplanted into nude mice. IgG1, IgG2b, and IgG2a isotype variants of the anti-CD19 mAb (CLB-CD19) were tested for their capacity to inhibit the growth of 10 x 10(6) Daudi cel...

متن کامل

New monoclonal antibodies for non-Hodgkin's lymphoma.

The anti-CD20 rituximab represents the first widely available antibody for the treatment of cancer based on significant singleagent activity in indolent lymphoma [1]. In diffuse large B-cell lymphoma (DLBCL), the incorporation of rituximab with standard chemotherapy improves survival [2]. However, while it is clear that the use of rituximab has had a significant impact in improving outcomes in ...

متن کامل

a new approach to credibility premium for zero-inflated poisson models for panel data

هدف اصلی از این تحقیق به دست آوردن و مقایسه حق بیمه باورمندی در مدل های شمارشی گزارش نشده برای داده های طولی می باشد. در این تحقیق حق بیمه های پبش گویی بر اساس توابع ضرر مربع خطا و نمایی محاسبه شده و با هم مقایسه می شود. تمایل به گرفتن پاداش و جایزه یکی از دلایل مهم برای گزارش ندادن تصادفات می باشد و افراد برای استفاده از تخفیف اغلب از گزارش تصادفات با هزینه پائین خودداری می کنند، در این تحقیق ...

15 صفحه اول

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
international journal of molecular and cellular medicine

جلد ۴، شماره ۳، صفحات ۱۴۳-۱۵۱

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023